Suche
Datum der Veröffentlichung: 2023-09-15
According to Interferon Market Research Report published by QY Forschung, this report covers market data, market hotspots, policy plans, competitive intelligence, market outlook forecasts and future development trends, predicts the direction of the Interferon industry, emerging hotspots, market space, technological trends, and future development trends.
Chronic hepatitis B is a chronic inflammatory disease of the liver caused by persistent infection with hepatitis B virus. According to the latest data on the incidence of hepatitis B released in the 2021 China Health and Wellness Statistical Yearbook, the number of new cases of hepatitis B was relatively stable at around 950,000 from 2013 to 2016, and then began to show a growth trend in 2017, exceeding 1 million, until 2019, the number of new cases of hepatitis B did not change much and basically remained above 1 million.
According to China's Guidelines for the Prevention and Control of Chronic Hepatitis B, antiviral treatment is chronic hepatitis B treatment. Chronic hepatitis B antiviral drugs mainly include nucleotide analogues and interferon analogues, of which polyethylene glycol interferon alpha (Peg-IFNα), entecavir (ETV), and tenofovir disoproxil (TDF) are the first-line drugs recommended by the guideline.
As it is difficult to completely cure hepatitis B, the ideal treatment goal recommended by the latest domestic and international guidelines for the prevention and treatment of chronic hepatitis B is clinical cure or functional cure, i.e., patients with chronic hepatitis B who have undergone treatment remain HBsAg negative (with or without HBsAb), HBVDNA undetectable, and liver function indexes are normal after stopping treatment.
According to relevant statistics, there are about 350 million hepatitis B virus carriers in the world, and about 100 million of them are in China (accounting for 29% of the total, with more than 30 million patients), and about 700,000 viral hepatitis-related deaths in the world each year account for nearly half of the total number of deaths in China.
In terms of the incidence of hepatitis B in China, although the overall incidence of hepatitis B in China has been declining in recent years, China is still a highly endemic area of hepatitis B virus in the world.
Nucleotide analogues mainly maintain response in treatment through inhibition of reverse transcriptase and other inhibitors, interfering with the replication of the genetic material of the hepatitis B virus, thus exerting therapeutic effects. Interferon is a broad-spectrum antiviral agent, a group of host-specific proteins secreted by multicellular cells in the presence of certain infections, etc. It has the dual focus of inhibiting viral replication and enhancing immunity: one is to inhibit viral replication and the other is to enhance immunity. In addition, there are significant differences between the two drugs in terms of administration and duration of treatment.
Interferon is a broad-spectrum antiviral agent that inhibits both RNA and DNA viruses. It does not directly kill or inhibit viruses, but rather blocks viral reproduction by acting on cell surface receptors and causing cells to produce antiviral proteins. At the same time, interferon can also directly activate immune cells, or indirectly inhibit the process of viral replication, which can inhibit the growth and reproduction of viruses during the early stages of viral infection in the body.
Domestic interferon drugs are mainly used in the antiviral treatment of hepatitis B and C. With the listing of oral antiviral drugs with better efficacy, the sales of interferon drugs have been declining year by year. However, by analysing the changes in the domestic interferon drug market, it is found that the sales of domestically produced interferon have been growing year by year despite the decline in the overall domestic interferon market size, while the market share of the interferon industry is also increasing year by year, from interferon industry market share of 32.45% to 65.25%. Therefore, the future of interferon domestic replacement is the domestic enterprise sales growth point.
With two chronic hepatitis B antiviral treatment Interferon drugs are divided into short-acting interferon: mainly including interferon α-1b (IFNα-1b), interferon α-2a (IFNα-2a), interferon α-2b (IFNα-2b)) and long-acting interferon: mainly including polyethylene glycol interferon α-2a (PegIFNα-2a), polyethylene glycol interferon α-2b ( PegIFNα-2b)). Long-acting interferon has more stable blood concentration and can be injected once a week to ensure stable blood concentration, which has the advantages of more convenient dosing and better efficacy than ordinary interferon.
For many years, China's long-acting interferon market has been monopolised by Roche and Merck Sharp & Dohme, but the company's long-acting interferon pegfilgrastim was approved for listing in 2016, breaking the monopoly of foreign investors and achieving rapid sales growth. According to the statistics, in 2018, the market share of pegabine reached 25.20%; in the field of polyethylene glycol α-2b injection, it even replaced the market of Merck Sharp & Dohme Pellegrinoe, with a sales volume of 25.98 million in 2018, which accounted for 97% of the market share of polyethylene glycol α-2b injection.
At present, there is no long-acting interferon product approved for chronic hepatitis B indications except for pegabine, paroxetine and pelargonium, but other similar products may be approved for chronic hepatitis B treatment in the future, intensifying competition in the industry. In addition, if the research and development of new target drugs for the treatment of chronic hepatitis B get a breakthrough in the future, it will have a greater impact on the long-acting interferon market.
Compared with developed countries, China for the treatment of hepatitis B, hepatitis C oral drugs into the market for a shorter period of time, the replacement of interferon is relatively limited, the short-term domestic interferon will benefit from China's rapid growth in the market of liver disease treatment drugs to achieve import substitution. However, in the long run, the market share of oral drugs for liver disease will continue to climb, which will have a greater impact on the domestic interferon market.
The above data refer to the market research report "2023-2029 Global and China Interferon Market Status and Future Development Trends" published by QY Forschung, we provide professional market research reports, market research reports, feasibility studies, IPO consulting, business plans and other services, especially in the field of chemical and mechanical constructed to solve the problem for the customers of the Bureau of Statistics, Customs, associations and other Official units can not be counted to the breakdown of product data, which is always in the industry in the unshakeable professional advantage of the reason.
Previous:
Revolutionising the plastic fittings industry: trends and developments
Nächste:
Microbiology Testing Industry Research : Global Market Size of USD 20.76 Billion by 2022
.cUk9jrBY.webp)
Erfahrene Experten, die die Probleme Ihrer Branche lösen und einen echten Mehrwert für Ihr Unternehmen schaffen
.RbCOXQaH.webp)
USA:
Indien:
Peking:
UK:
+1-6262952442
+91-9766478224
+86-1082945717
0044-203-734-8135